DICUMAROL manufacturers and suppliers in india

DICUMAROL

Properties

Melting point:: 290-292 °C(lit.)

Boiling point:: 392.79°C (rough estimate)

Density: 1.2864 (rough estimate)

refractive index: 1.4450 (estimate)

storage temp.: Sealed in dry,Room Temperature

solubility: DMSO:3.06(Max Conc. mg/mL);9.1(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:1):0.5(Max Conc. mg/mL);1.49(Max Conc. mM)
DMF:1.25(Max Conc. mg/mL);3.72(Max Conc. mM)
Water:50.0(Max Conc. mg/mL);148.68(Max Conc. mM)

pka: 4.20±1.00(Predicted)

form: Fine Crystalline Powder

color: White

Water Solubility: Soluble in aqueous alkaline solutions, organic bases, 0.1 N NaOH (15 mg/ml), Pyridine (50 mg/ml), chloroform (slightly soluble), and benzene (slightly soluble). Insoluble in water, and alcohols.

Merck: 14,3090

Safety Information

Symbol(GHS): GHS06,GHS08,GHS09

Signal word: Danger

Hazard statements: H301-H372-H411

Precautionary statements: P260-P264-P270-P273-P301+P310-P314

Hazard Codes: T,N

Risk Statements: 22-48/25-51/53

Safety Statements: 37-45-61

RIDADR: UN 2811 6.1/PG 3

WGK Germany: 3

RTECS: GN7875000

TSCA: Yes

HazardClass: 6.1(b)

PackingGroup: III

HS Code: 29322985

Toxicity: LD50 orally in rats: 541.6 mg/kg (Rose)

Use

Dicumarol is used alone or as an adjunct to heparin in theprophylaxis and treatment of intravascular clotting. It is usedin postoperative thrombophlebitis, pulmonary embolus, acuteembolic and thrombotic occlusion of peripheral arteries, andrecurrent idiopathic thrombophlebitis. It has no effect on analready-formed embolus but may prevent further intravascularclotting. Because the outcome of acute coronary thrombosisdepends largely on extension of the clot and formation ofmural thrombi in the heart chambers, with subsequent embolization,dicumarol has been used in this condition. It hasalso been administered to arrest impending gangrene afterfrostbite. The dose, after determination of the prothrombinclotting time, is 25 to 200 mg, depending on the size and thecondition of the patient. The drug is given orally in the formof capsules or tablets. On the second day and thereafter, itmay be given in amounts sufficient to maintain the prothrombinclotting time at about 30 seconds. If hemorrhages shouldoccur, a dosage of 50 to 100 mg of menadione sodium bisulfiteis injected, supplemented by a blood transfusion.